ABSTRACT
TEC Indications: Lymphomas, carcinomas Category: Antineoplastic Half-life: terminal: 4-15 hours Clinically important, potentially hazardous interactions with: aldesleukin,
cyclosporine, St John’s wort
Reactions
Skin Allergic reactions (sic) (1-2%)
Diaphoresis Ecchymoses Eccrine squamous syringometaplasia (1997): Valks R+, Arch Dermatol 133, 873 Erythema (1994): Portal I+, Cancer Chemother Pharmacol 34, 181 (acral) (1993): Dechaufour F+, Ann Dermatol Venereol (French) 120, 219 (acral) (1993): Vukelja SJ+, Cutis 52, 89 (acral) Erythema multiforme (1987): Yokel BK+, J Cutan Pathol 14, 326 Exanthems (1992): Beyer J+, Bone Marrow Transplant 10, 491 (1992): Breathnach SM+, Adverse Drug Reactions and the Skin Blackwell, Oxford,
301 (passim) (1987): Yokel BK+, J Cutan Pathol 14, 326 (1981): Weiss RB+, Ann Intern Med 94, 66 Facial edema Flushing (<1%) (1990): Henwood JM+, Drugs 39, 438 (1988): Ogle KM+, Am J Clin Oncol 11, 663 (1985): Tucci E+, Chemioterapia 4, 460 Infections (2002): Evans SR+, J Clin Oncol 20(15), 3236 Pigmentation
(2001): Mutafoglu-Uysal K+, Turk J Pediatr 43(2), 172 (1991): Singal R+, Pediatr Dermatol 8, 231 Pruritus Purpura Radiation recall (1993): Williams BJ+, Clin Exp Dermatol 18, 452 (ultraviolet) (1992): Breathnach SM+, Adverse Drug Reactions and the Skin Blackwell, Oxford,
301 (passim) (1987): Yokel BK+, J Cutan Pathol 14, 326 Rash (sic) Stevens-Johnson syndrome (1992): Breathnach SM+, Adverse Drug Reactions and the Skin Blackwell, Oxford,
301 (passim) (1987): Yokel BK+, J Cutan Pathol 14, 326 (1983): Jameson CH+, Cancer Treat Rep 67, 1050 Urticaria
Hair Hair-alopecia (8-66%)
(1990): Henwood JM+, Drugs 39, 438 (100%, dose-dependent) (1989): Smit EF+, Thorax 44, 631 (1989): Wander HE+, Cancer Chemother Pharmacol 24, 261 (1989): Yoshino M+, Jpn J Clin Oncol 19, 120 (57%)
Nails Nails-Beau’s lines (transverse nail bands)
(1994): Ben-Dayan D+, Acta Haematol 91, 89 Nails-onycholysis (1995): Obermair A+, Gynecol Oncol 57, 436
Other Anaphylactoid reactions (<2%)
(2003): Taguchi A+, Gan To Kagaku Ryoho 30(8), 1187 (1989): Siddall SJ+, Lancet 1, 394 (1989): Wander HE+, Cancer Chemother Pharmacol 24, 261 Dysgeusia Hypersensitivity (<1%) (2002): Siderov J+, Br J Cancer 86(1), 12 (2001): Mutafoglu-Uysal K+, Turk J Pediatr 43(2), 172 (1993): Hudson MM+, J Clin Oncol 11, 1080 (1992): Weiss RB, Semin Oncol 19, 458 (1991): Kellie SJ+, Cancer 67, 1070 (1988): Ogle KM+, Am J Clin Oncol 11, 663 (1985): Tucci E+, Chemioterapia 4, 460 (1984): O’Dwyer PJ+, Cancer Treat Rep 68, 959 Injection-site pain
Mucositis (>10%) Oral mucosal lesions (1990): Henwood JM+, Drugs 39, 438 (1-5%) Paresthesias Stomatitis (1-10%) Thrombophlebitis (<1%) Tongue edema
Trade name: Aromasin (Pharmacia) Indications: advanced breast cancer Category: Antineoplastic (steroidal aromatase inactivator) Half-life: 24 hours
Reactions
Skin Diaphoresis (6%)
(2000): Clemett D+, Drugs 59, 1279 (1997): Thurlimann B+, Eur J Cancer 33, 1767 (12%) Edema (7%) Flu-like syndrome Hot flashes (13%) (2002): Tabei T+, Can To Kagaku Ryoho 29(7), 1 199 (2000): Clemett D+, Drugs 59, 1279 (1999): Jones S+, J Clin Oncol 17, 3418 (1998): Paridaens R+, Anticancer Drugs 9, 675 (30%) (1997): Thurlimann B+, Eur J Cancer 33, 1767 (21%) Infections (sic) Peripheral edema (1997): Thurlimann B+, Eur J Cancer 33, 1767 (9%) Pruritus (2-5%) Rash (sic) (2-5%)
Hair Hair-alopecia (2-5%)
Other Headache
(2002): Tabei T+, Gan To Kagaku Ryocho 29(7), 1199
Hyperesthesia Lymphedema (2-5%) Paresthesias (2-5%) Tumor pain (1998): Paridaens R+, Anticoncer Drugs 9, 675 (30%)
Trade name: Zetia Indications: Hypercholesterolemia Category: Selective cholesterol-absorption inhibitor Half-life: 22 hours Clinically important, potentially hazardous interactions with: cyclosporine,
gemfibrozil, fenofibrate, HMG-CoA Inhibitors (statins)
Reactions
Skin Viral infections (2.2%)
Other Abdominal pain (2.2%)
Arthralgia (3.8%) Back pain (4.1%) Cough (2.3%) Myalgia (5%)
